Table 2.

Treatment-emergent adverse events (TEAEs) occurring in ≥20% of patients

	All patients (n = 40)
	All Grades	Grade 3	Grade 4
Hematologic TEAEs
Neutropenia	40 (100)	19 (47.5)	2 (5.0)
Leukopenia	40 (100)	13 (32.5)	1 (2.5)
Anemia	13 (32.5)	0	0
Thrombocytopenia	11 (27.5)	1 (2.5)	1 (2.5)
Non-hematologic TEAEs
Aspartate aminotransferase increased	16 (40.0)	0	0
Fatigue	15 (37.5)	0	0
Blood creatinine increased	14 (35.0)	0	0
Alanine aminotransferase increased	13 (32.5)	0	0
Headache	13 (32.5)	0	0
Alopecia	11 (27.5)	0	0
Bilirubin conjugated increased	10 (25.0)	0	0
Decreased appetite	9 (22.5)	0	0
Constipation	8 (20.0)	0	0
Dyspnoea	8 (20.0)	0	0

Data are n (%). No grade 5 adverse events occurred